physiotherapy, 2 x a week for 6 weeksbasal therapy, 2 x a week for 6 weeksStandard therapy group
physiotherapy, 2 x a week for 6 weeks: Only comprehensive and differentiated interventions provide the best care for people with special needs. Basal stimulation complements physiotherapy perfectly. The group will receive standard physiotherapy based on best clinical practice principles.
basal therapy, 2 x a week for 6 weeks: basal therapy, 2 x a week for 6 weeks
The aim of basal therapy will be to help patients with profound disabilities compensate for the lack of their own life experiences, including independent movement and interaction with the environment, strengthening the meaning and purpose of individual movements, stimulating movements, even minimal ones, and entering into contact with the external environment through various types of stimulation, offering numerous environmental stimuli and multi-sensory experiences that will facilitate awareness of one's own existence.
Each session will include:
1. preparation and adjustment of stimuli based on information regarding the assessment of the patient's condition and problems,
2. careful observation and appropriate care of the patient,
3. grading of stimuli and their appropriate stimulation,
4. recording the therapist's comments on the therapy card.
Standard therapy group: Both groups will receive standard therapy based on best clinical practice principles for 12 weeks.
Study summary
The aim of the study is to obtain knowledge of the impact of basal stimulation therapy on the health status of adults suffering from schizophrenia and requiring permanent institutional care.
The use of basal stimulation therapy in many European centres for several decades, combined with the limited amount of scientific evidence, justifies undertaking the proposed research. Available evidence indicates reduced anxiety and improved quality of life. No such studies have previously been conducted in institutionalized patients with schizophrenia.
Eligibility
Sex
ALL
Min age
55 Years
Max age
—
Healthy volunteers
No
Study inclusion criteria:
* women and men aged ≥ 55 years,
* consent of the legal guardian/caregiver to participate in the study,
* schizophrenia clinically confirmed for at least 5 years, with predominance of negative symptoms,
* stable drug therapy (treatment unchanged for at least 3 months)
* functional ability of everyday life on the Barthel scale below 40 points.
The exclusion criteria from the study will be:
* lack of consent to participate in the study;
* pregnancy
* general contraindications (acute inflammatory conditions and diseases accompanied by fever, venous thrombosis, unstable arterial hypertension , early condition after contrast-enhanced computed tomography, early condition after lumbar puncture, general serious condition of the patient )
* exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, visual seizures)
* active cancer;
* diseases of the nervous system (neuropathies, stroke , damage to the cerebellum, labyrinth) causing altered sensitivity to stimuli;
* diseases and illnesses of the musculoskeletal system that significantly disturb the body's balance and the mobility of the limbs;
* pressure ulcers grade IV and V on the Torrance scale.
Primary outcome measure(s)
Primary Outcome Measures - GCS — From enrollment to the end of treatment at 12 weeks Cognitive function testing with Glasgow coma scale (GCS). The Glasgow Coma Scale (GCS) measure patient' consciousness and cognitive functioning based on three specific checks: eye opening, verbal response, and motor response. The total score ranges from 3 to 15, where 15 means fully awake and 3 means deep unresponsiveness.
Primary Outcome Measures - CRS-R — From enrollment to the end of treatment at 12 weeks Cognitive function testing with Coma Recovery Scale (CRS-R) The Coma Recovery Scale-Revised (CRS-R) ranges from 0 to 23 points across six subscales (Auditory, Visual, Motor, Oromotor/Verbal, Communication, and Arousal). Higher scores indicate higher levels of conscious awareness.
Primary Outcome Measures - blood test — From enrollment to the end of treatment at 12 weeks Blood concentration testing for selected biological factors. Patients will have 5 ml of venous blood drawn twice (before and after completing the exercise) to perform the blood test.
Trial sites (2)
Facility
City
Region
Status
Jerzy Kukuczka Academy of Physical Education in Katowice, Poland
Katowice
Silesian Voivodeship
Clinical Psychiatric Hospital SPZOZ in Rybnik, Poland
Rybnik
Silesian Voivodeship
More The Jerzy Kukuczka Academy of Physical Education in Katowice trials in Poland
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.